A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Latest Information Update: 06 May 2021
At a glance
- Drugs Linaclotide (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Actavis; Forest Laboratories
- 30 Nov 2015 According to an Ironwood Pharmaceuticals media release, positive top-line results are published.
- 30 Nov 2015 According to an Ironwood Pharmaceuticals media release, primary endpoint (Change from baseline in the 8-week Spontaneous Bowel Movement (SBM) frequency rate (SBMs/week) during the Treatment Period) has been met.
- 03 Nov 2015 According to an Ironwood Pharmaceuticals media release, data from this study is expected to be available in the fourth quarter of 2015.